DIABETES MANAGEMENT AND THE ROLE OF THE NURSE IN THE COVID-19 EPIDEMIC

Abstract

COVID-19 SALGININDA DİYABET YÖNETİMİ VE HEMŞİRENİN ROLÜ

Öz

ÖZET Çin’in Wuhan şehrinde, Aralık 2019 tarihinde görülmeye başlayan, SARS-CoV-2 (şiddetli akut solunum sendromu koronavirüsü-2) olarak adlandırılan, yeni tip koronavirüsün şiddetli akut solunum sendromuna neden olduğu belirlenmiş ve acil durum ilan edilmiştir. Yapılan araştırmalarda COVID-19 enfeksiyonu için komorbidetelerin varlığı, obezite, ileri yaş gibi faktörlerin kötü prognozu öngösterdiği belirlenmiştir. COVID-19 ile diyabetin etkileşimli patofizyolojik mekanizmaları nedeniyle, COVID-19 sürecinde diyabetin etkin yönetimi oldukça önem arz etmektedir. Diyabet yönetiminin mevcut zorluklarına, COVID-19 salgının bireylerin yaşamlarına getirdiği yüklerin eklenmesi ile sürecin daha kompleks bir hal aldığı görülmüştür. COVID-19 salgınının yaşattığı kriz ile mücadele edilirken, diyabet bakımını iyileştirmek için de yeni stratejiler, eylem planları, yönergeler geliştirmeli ve bu planlamaların hızlıca uygulamaya dökülmesi gerekmektedir. Pandemi sürecinde diyabetin etkin yönetimi için de multidisipliner ekip yaklaşımı gerektirmektedir ve diyabet hemşirelerine önemli rol ve sorumluluklar düşmektedir. Salgın sürecinde, diyabet hemşirelerinin uygulayacağı bakım; diyabetli bireyin yaşamına getirdiği yüklerin azaltılması ile hedeflenen glisemik değerlerin sürdürülmesine, diyabetin akut komplikasyonların önlenmesine, acil başvurularının azaltılmasına, gereksiz hastane başvurularının önlenmesine, hastaneye yatışların engellenmesine, hastanede kalış süresinin azaltılmasına, komplikasyon oranlarının düşürülmesine, kontrolsüz diyabetin sağlık hizmetlerine getirdiği yükün en aza indirgenmesine, sağlık personelinin bakım yükünün azaltılmasına, diyabetli bireyin yaşam kalitesinin iyileştirilmesine ve en önemlisi COVID-19 risklerinin azaltılmasına katkı sağlayacaktır.

Anahtar Kelimeler

• COVID-19
• Pandemi
• Diyabet
• Diyabet Yönetimi
• Diyabet Hemşireliği

Kaynakça

1. KAYNAKÇA 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi: 10.1056/NEJMoa2001017.
2. 2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427
3. 3. Li H, Liu Z, Ge J. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. J Cell Mol Med. 2020;24(12):6558-6570. doi: 10.1111/jcmm.
4. 4. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254-266. doi:10.1016/j.cca.2020.05.044
5. 5. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al.The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;13:7(1):11. doi: 10.1186/s40779-020-00240-0.
6. 6. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR et al. The ıncubation period of coronavirus disease 2019 (covıd-19) from publicly reported confirmed cases: estimationand application. Ann Intern Med. 2020;172(9):577-582. doi:10.7326/M20-0504
7. 7. Centers for Diasease Control and Prevention. Symptoms of Coronavirus 2020. Erişim Tarihi:09.09.2020 https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
8. 8. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res. 2020;188:109819. doi:10.1016/j.envres.2020.109819

9. 9. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS -CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765. doi:10.1371/journal.pone.0234765
10. 10. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
11. 11. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
12. 12. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720.
13. 13. Chen N, Zhou M, Dong X. Qu, J., Gong, F., Han, Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 : 507–513.
14. 14. YingJie Z, Zhu C, Jin L, XingLong Y, Jing L, Yue Y, et al.Clinical and epidemiological characteristics of 26 patients diagnosed with COVID-19. Chinese Journal of Nosocomiology, 30(6), 826-829.
15. 15. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of general internal medicine, 2020;35(5):1545-1549.
16. 16. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.
17. 17. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q,et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017.
18. 18. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020;14(4):283-287. doi: 10.1016/j.dsx.2020.03.016.
19. 19. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
20. 20. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-8. doi: 10.1111/j.1464-5491.2006.01861.x.
21. 21. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33(7):1491-1493. doi:10.2337/dc09-2215
22. 22. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-133. doi:10.1016/j.ijid.2016.06.015
23. 23. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immunedys regulation and enhanced disease severity following MERS-CoVinfection. JCI Insight. 2019;4(20):e131774. doi:10.1172/jci.insight.131774
24. 24. Yang YM, Hsu CY, Lai CC, et al. Impact of comorbidity on fatality rate of patients with Middle East respiratory syndrome. Sci Rep. 2017;7(1):11307. doi:10.1038/s41598-017-10402-1
25. 25. Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, Alanazi MS, Mohamed N, Alrasheed MM, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospectivestudy . Epidemiol Infect. 2018(5);147:1-5. doi: 10.1017/S0950268818002923.
26. 26. TEMD. Diabetes Mellitus ve Komplikasyonlarının Tanı Tedavi ve İzlem Kılavuzu. Türk Endokrinoloji Metabolizma Derneği, 2020.
27. 27. Hoffmann M, Kleine-Weber H, Krüger N, Mueller MA, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv (2020).
28. 28. Kutlutürk F . [COVID-19 pandemic and diabetes mellitus]. Turk J Diab Obes. 2020; 4(2): 130-137.
29. 29. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;31:e3319. doi: 10.1002/dmrr.3319.
30. 30. Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;162:108132. doi:10.1016/j.diabres.2020.108132
31. 31. TDV. [COVID-19 Pandemic diabetes follow-up and treatment criteria consensus report].Türk Diyabet Vakfı, 2020.
32. 32. Kim NY, Ha E, Moon JS, Lee YH, Choi EY. Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports. Diabetes Metab J. 2020;44(2):349-353. doi: 10.4093/dmj.2020.0091.
33. 33. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi: 10.1016/j.diabres.2020.108142.
34. 34. Zhou J, Tan J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020;107:154216. doi:10.1016/j.metabol.2020.154216
35. 35. Caballero AE, Ceriello A, Misra A, Aschner P, McDonnell ME, Hassanein M, et al. COVID-19 in people living with diabetes: An international consensus. J Diabetes Complications. 2020;34(9):107671. doi: 10.1016/j.jdiacomp.2020.107671.
36. 36. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID‐19) epidemic among the general population in China. Int J Environ Res Public Health 2020; 17: pii: E1729.
37. 37. Wang W., Shan Z., Wang G. Expert recommendations for diabetes management in primary care during the COVID-19 pandemic. Chin J Endocrinol Metab. 2020;36:185–190. doi: 10.3760/cma.j.cn311282-20200226-00106.
38. 38. Ji L., Li G., Gong Q. Guidance on diabetes management in the elderly during the COVID-19 pandemic. Chin J Diabetes. 2020;28:1–6. 39. Diabetes Canada. COVID-19 (coronavirus) and diabetes. Erişim Tarihi:1.10.2020 https://www.diabetes.ca/campaigns/covid-19-(coronavirus)-and-diabetes
39. 40. International Diabetes Federation. COVID-19 and diabetes. Erişim Tarihi:1.10.2020 https://www.idf.org/aboutdiabetes/what-is-diabetes/covid-19-and-diabetes/1-covid-19-and-diabetes.html
40. 41. American Diabetes Association. Diabetes and Coronavirüs. Erişim Tarihi:1.10.2020 https://www.diabetes.org/coronavirus-covid-19
41. 42. Association of Diabetes Care & Education Specialist. Practical support for those managing diabetes during challenging times. Erişim Tarihi: 1.10.2020 https://nf01.diabeteseducator.org/eweb/DynamicPage.aspx?webcode=EventInfo®_evt_key=f05ab328-53ce-423f-964e-284f4539bb55&RegPath=EventRegFees
42. 43. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology. 2020;14(4):813-821. doi:10.1177/1932296820924469
43. 44. Ghosh A, Arora B, Gupta R, Anoop S, Misra A. Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020;14(5):917-920. doi:10.1016/j.dsx.2020.05.044
44. 45. Misra A., Bloomgarden Z. Diabetes during the COVID-19 pandemic: a global call to reconnect with patients and emphasize lifestyle changes and optimise glycemic and blood pressure control. J Diabetes. 2020 May;17 doi: 10.1111/1753-0407.13048.
45. 46. Gopalan HS, Misra A. COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India. Diabetes Metab Syndr. 2020;14(5):757-759. doi: 10.1016/j.dsx.2020.05.041. ,
46. 47. Verma A, Rajput R, Verma S, Balania VKB, Jangra B. Impact of lockdown in COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus. Diabetes Metab Syndr. 2020;14(5):1213-1216. doi:10.1016/j.dsx.2020.07.016
47. 48. Joensen LE, Madsen KP, Holm L, Nielsen KA, Rod MH, Petersen AA, Rod NH, Willaing I. Diabetes and COVID-19: psychosocial consequences of the COVID-19 pandemic in people with diabetes in Denmark-what characterizes people with high levels of COVID-19-related worries? Diabet Med. 2020;37(7):1146-1154. doi:10.1111/dme.14319.
48. 49. TEMD.COVID-19 Bilgilendirme ve sık sorulan sorular.2020. http://temd.org.tr/covid-19-bilgilendirme-ve-sikca-sorulan-sorular Erişim Tarihi:20.09.20
49. 50. TEMD.COVID-19 Bilgilendirme ve hekimler için sorular.2020. http://temd.org.tr/covid-19-bilgilendirme-ve-hekimler-icin-sorular Erişim Tarihi:20.09.20
50. 51. Türk Diyabet Cemiyeti. Türk diyabet cemiyeti’nden yeni koronavirüs infeksiyonu (Covid-19)
51. 52. Türkiye Diyabet Vakfı.Siz evde kalın,biz yanınızdayız!.2020. https://www.turkdiab.org/haberler.asp?lang=TR&id=166 Erişim Tarihi:20.09.2020
52. 53. Schofield J, Leelarathna L, Thabit H. COVID-19: Impact of and on Diabetes. Diabetes Ther. 2020;11(7):1429-1435. doi:10.1007/s13300-020-00847-5
53. 54. Rogers LC, Lavery LA, Joseph WS, Armstrong DG. All Feet On Deck-The Role of Podiatry During the COVID-19 Pandemic: Preventing hospitalizations in an over burdened healthcare system, reducing amputation and death in people with diabetes. J Am Podiatr Med Assoc. 2020;10.7547/20-051. doi:10.7547/20-051
54. 55. Ghosh A, Arora B, Gupta R, Anoop S, Misra A. Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020;14(5):917-920. doi:10.1016/j.dsx.2020.05.044
55. 56. Fuchs J, Hovorka R. COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare? Journal of Diabetes Science and Technology. 2020;14(4):735-736. doi:10.1177/1932296820929714
56. 57. Schofield J, Leelarathna L, Thabit H. COVID-19: Impact of and on Diabetes. Diabetes Ther. 2020;11(7):1429-1435. doi:10.1007/s13300-020-00847-5
57. 58. Drucker DJ. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. Endocr Rev. 2020;41(3):bnaa011. doi:10.1210/endrev/bnaa011
58. 59. Wicaksana AL, Hertanti NS, Ferdiana A, Pramono RB. Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: A scoping review. Diabetes Metab Syndr. 2020;14(5):1109-1120. doi:10.1016/j.dsx.2020.06.070
59. 60. Peters AL, Garg SK. The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020 Jun;22(6):449-453. doi: 10.1089/dia.2020.0187.
60. 61. Nørgaard K. Telemedicine Consultations and Diabetes Technology During COVID-19. J Diabetes Sci Technol. 2020;14(4):767-768. doi: 10.1177/1932296820929378.
61. 62. Mukona DM, Zvinavashe M. Self- management of diabetes mellitus during the Covid-19 pandemic: Recommendations for a resource limited setting. Diabetes Metab Syndr. 2020;14(6):1575-1578. doi:10.1016/j.dsx.2020.08.022
62. 63. Banerjee M, Chakraborty S, Pal R. Diabetes self-management amid COVID-19 pandemic. Diabetes Metab Syndr. 2020;14(4):351-354. doi:10.1016/j.dsx.2020.04.013
63. 64. Jendle J. The Use of eHealth for the Care of Patients With Diabetes in Connection to the COVID-19 Pandemic. J Diabetes Sci Technol. 2020 Jul;14(4):739-740. doi: 10.1177/1932296820922623.
64. 65. Jaly I, Iyengar K, Bahl S, Hughes T, Vaishya R. Redefining diabetic foot disease management service during COVID-19 pandemic. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):833-838. doi: 10.1016/j.dsx.2020.06.023.
65. 66. Sinclair A, Dhatariya K, Burr O, Nagi D, Higgins K, Hopkins D,et al. Guidelines for the management of diabetes in care homes during the Covid‐19 pandemic. Diabetic Medicine, 2020;37(7):1090-1093.
66. 67. Hartmann-Boyce J, Morris E, Goyder C, Kinton J, Perring J, Nunan D,et al. Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care. 2020;43(8):1695-1703. doi: 10.2337/dc20-1192
67. 68. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2015;2015(9):CD002098. doi: 10.1002/14651858.CD002098.pub2.
68. 69. McDonnell ME. Telemedicine in Complex Diabetes Management. Curr Diab Rep. 2018;18(7):42. doi: 10.1007/s11892-018-1015-3. PMID: 29797292.
69. 70. Sacks LJ, Pham CT, Fleming N, Neoh SL, Ekinci EI. Considerations for people with diabetes during the Coronavirus Disease (COVID-19) pandemic. Diabetes Res Clin Pract. 2020;166:108296. doi:10.1016/j.diabres.2020.108296